Torqur AG

Our key product is bimiralisib (PQR309), a dual pan-PI3K and mTOR inhibitor. Such simultaneous inhibition of the ATP site of all class-I PI3K isoforms and mTORC1 and mTORC2 is Torqur’s preferred strategy to reduce tumor growth and slows down cancer cell metastasis. Furthermore, blocking the PI3K/mTOR cascade on both levels minimizes the possibility of cancer cells developing drug resistance. Bimiralisib is a small molecular weight chemical compound that penetrates the blood-brain barrier showing potent anti-proliferative in vitro activity against a series of tumor cell lines and in vivo antitumor efficacy. Bimiralisib has been investigated in multiple oncology phase 1/2 clinical trials in various indications where different dosing schedules have been explored. Bimiralisib demonstrated early clinical signs of efficacy and good tolerability with the intermittent dosing schedules enabling the opportunity for further development as a monotherapy and/or in combination with other therapies. Bimiralisib is a small achiral molecule with favorable pharmacokinetic parameters in different preclinical models. Oral administration of Bimiralisib in clinical development showed encouraging activity and acceptable safety profile in advanced solid tumours and R/R lymphoma. Bimiralisib is a suitable candidate for the treatment of other indications. As a brain penetrant, the drug could allow the treatment of brain tumors, brain metastasis, and different neurological disorders. Its topical application could be applied against certain skin cancers and dermatological conditions.